Arjan Malekzadeh1, Harry Twaalfhoven2, Nienke J Wijnstok3, Joep Killestein4, Marinus A Blankenstein5, Charlotte E Teunissen6. 1. Department of Clinical Chemistry, VU University Medical Center, Amsterdam, The Netherlands. Electronic address: a.malekzadeh@vumc.nl. 2. Department of Clinical Chemistry, VU University Medical Center, Amsterdam, The Netherlands. Electronic address: h.twaalfhoven@vumc.nl. 3. Department of Internal and Vascular Medicine, VU University Medical Center, Amsterdam, The Netherlands. Electronic address: nienke.wijnstok@gmail.com. 4. Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands. Electronic address: j.killestein@vumc.nl. 5. Department of Clinical Chemistry, VU University Medical Center, Amsterdam, The Netherlands. Electronic address: ma.blankenstein@vumc.nl. 6. Department of Clinical Chemistry, VU University Medical Center, Amsterdam, The Netherlands. Electronic address: c.teunissen@vumc.nl.
Abstract
BACKGROUND: The levels of pro and anti-inflammatory cytokines can be altered in different autoimmune pathologies, such as multiple sclerosis (MS). It is likely that cytokines in bodily fluids can provide a good reflection of ongoing disease patho-physiology. In this study we aimed to validate multiplex cytokine platforms and evaluate whether these cytokines are differentially expressed in MS. METHODS: Assay validation for simultaneous quantification of IL-1β, IL-6, IL-8 and TNF-α in serum and CSF were performed using both the Luminex-xMAP (Luminex) and Meso Scale Discovery (MSD) platforms. Next, the relation of the pro-inflammatory cytokine 4-plex with disease progression, symptoms and subtypes was studied in paired serum and CSF of MS patients (n=56), and compared with healthy controls (n=203), with the use of the MSD-platform. RESULTS: The MSD-platform showed overall better assay characteristics such as, sensitivity, recovery and linearity compared to the Luminex for the 4-plex cytokines in CSF and serum. IL-6, IL-8 and TNF-α (p<0.001) levels were significantly increased in MS serum compared to healthy controls. Moreover, serum IL-1β levels correlated with expanded disability status scale (EDSS) scores (r=-0.34, p<0.05). Additionally, IL-6 and IL-8 CSF levels were both significantly decreased in MS patients compared to non-inflammatory neurological disease controls. Noteworthy, higher IL-8 CSF levels than IL-8 serum levels were observed for MS patients, indicating intrathecal activation of macrophages in MS. CONCLUSION: We have demonstrated that the pro-inflammatory 4-plex kit of the MSD-platform shows better assay characteristics in comparison with Luminex kit for quantification of these cytokines in serum and CSF. Overall, the increased levels of IL-6, IL-8 and TNF-α in serum of MS patients compared to healthy controls, support the use of multiple cytokines for future MS biomarker and disease progression research. Copyright Â
BACKGROUND: The levels of pro and anti-inflammatory cytokines can be altered in different autoimmune pathologies, such as multiple sclerosis (MS). It is likely that cytokines in bodily fluids can provide a good reflection of ongoing disease patho-physiology. In this study we aimed to validate multiplex cytokine platforms and evaluate whether these cytokines are differentially expressed in MS. METHODS: Assay validation for simultaneous quantification of IL-1β, IL-6, IL-8 and TNF-α in serum and CSF were performed using both the Luminex-xMAP (Luminex) and Meso Scale Discovery (MSD) platforms. Next, the relation of the pro-inflammatory cytokine 4-plex with disease progression, symptoms and subtypes was studied in paired serum and CSF of MS patients (n=56), and compared with healthy controls (n=203), with the use of the MSD-platform. RESULTS: The MSD-platform showed overall better assay characteristics such as, sensitivity, recovery and linearity compared to the Luminex for the 4-plex cytokines in CSF and serum. IL-6, IL-8 and TNF-α (p<0.001) levels were significantly increased in MS serum compared to healthy controls. Moreover, serum IL-1β levels correlated with expanded disability status scale (EDSS) scores (r=-0.34, p<0.05). Additionally, IL-6 and IL-8 CSF levels were both significantly decreased in MS patients compared to non-inflammatory neurological disease controls. Noteworthy, higher IL-8 CSF levels than IL-8 serum levels were observed for MS patients, indicating intrathecal activation of macrophages in MS. CONCLUSION: We have demonstrated that the pro-inflammatory 4-plex kit of the MSD-platform shows better assay characteristics in comparison with Luminex kit for quantification of these cytokines in serum and CSF. Overall, the increased levels of IL-6, IL-8 and TNF-α in serum of MS patients compared to healthy controls, support the use of multiple cytokines for future MS biomarker and disease progression research. Copyright Â
Authors: K B Casaletto; F M Elahi; R Fitch; S Walters; E Fox; A M Staffaroni; B M Bettcher; H Zetterberg; A Karydas; J C Rojas; A L Boxer; J H Kramer Journal: Cytokine Date: 2018-06-14 Impact factor: 3.861
Authors: Veit Rothhammer; Davis M Borucki; Jessica E Kenison; Patrick Hewson; Zhongyan Wang; Rohit Bakshi; David H Sherr; Francisco J Quintana Journal: Sci Rep Date: 2018-03-21 Impact factor: 4.379
Authors: Heather C Lasseter; Allison C Provost; Lauren E Chaby; Nikolaos P Daskalakis; Magali Haas; Andreas Jeromin Journal: Cytokine X Date: 2020-04-28
Authors: Cutter A Lindbergh; Breton M Asken; Kaitlin B Casaletto; Fanny M Elahi; Lauren A Goldberger; Corrina Fonseca; Michelle You; Alexandra C Apple; Adam M Staffaroni; Ryan Fitch; Will Rivera Contreras; Paul Wang; Anna Karydas; Joel H Kramer Journal: J Gerontol A Biol Sci Med Sci Date: 2021-10-13 Impact factor: 6.591
Authors: Charlotte E Teunissen; Markus Otto; Sebastiaan Engelborghs; Sanna-Kaisa Herukka; Sylvain Lehmann; Piotr Lewczuk; Alberto Lleó; Armand Perret-Liaudet; Hayrettin Tumani; Martin R Turner; Marcel M Verbeek; Jens Wiltfang; Henrik Zetterberg; Lucilla Parnetti; Kaj Blennow Journal: Alzheimers Res Ther Date: 2018-03-15 Impact factor: 6.982
Authors: Eiva Bernotiene; Edvardas Bagdonas; Gailute Kirdaite; Paulius Bernotas; Ursule Kalvaityte; Ilona Uzieliene; Christian S Thudium; Heidi Hannula; Gabriela S Lorite; Mona Dvir-Ginzberg; Ali Guermazi; Ali Mobasheri Journal: Front Med (Lausanne) Date: 2020-10-21